Autoimmune hemolytic anemia in refractory hairy cell leukemia on dabrafenib and trametinib
Hairy cell leukemia (HCL) is a rare, indolent B cell malignancy characterized by bone marrow infiltration, splenomegaly, pancytopenia, and neoplastic cells morphologically with cytoplasmic “hair-like” projections . Analogous to other B cell disorders, autoimmune diseases have been reported in HCL; however, autoimmune hemolytic anemia (AIHA) has seldom been reported [2, 3].
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Bouroncle BA, Wiseman BK, Doan CA (1958) Leukemic reticuloendotheliosis. Blood. 13(7):609–630Google Scholar
- 5.Mhawech-Fauceglia P, Oberholzer M, Aschenafi S, Baur A, Kurrer M, Von Rohr A et al (2006) Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. Arch Pathol Lab Med 130:374–377Google Scholar
- 7.Grob JJ, Flaherty KT, Long GV, Nathan PD, Schadendorf D, Ribas A, Robert C, Lane SR, Mak C, Legenne P, Davies MA (2016) Pooled analysis of safety with extended 3-year follow-up across combination dabrafenib and trametinib phase 3 trials. J Clin Oncol 34(15_suppl):9534–9534. https://doi.org/10.1200/JCO.2016.34.15_suppl.9534 CrossRefGoogle Scholar